A doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/85440
Title:
A doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphoma.
Authors:
Wylie, James P; Cowan, Richard A ( 0000-0001-9004-8136 ) ; Radford, John A ( 0000-0001-7898-2786 ) ; Deakin, David P; Harris, Maggie A; Wilkinson, Peter M
Abstract:
A retrospective analysis was performed on 66 patients, aged 70 years or older, who received treatment with a weekly doxorubicin-containing regimen (VAPEC-B) for high grade non-Hodgkin's lymphoma (NHL). Two dosing schedules were employed. The choice of regimen was at the discretion of the treating clinician and reflected the performance status of the patient and the predicted tolerance to chemotherapy. Forty-nine patients received a half-dose schedule and 17 the full-dose schedule. Those receiving the half-dose regimen had a lower median performance status and received a lower dose intensity of chemotherapy (45% versus 83%). However, the outcomes of the two groups were similar: complete remission rate 41% versus 47%, and 5-year overall survival 36% versus 23%, for the half- and full-dose groups, respectively. A similar proportion of patients (51% versus 59%) completed each regimen, although there were more delays in treatment delivery experienced in those receiving the full dose. Half-dose VAPEC-B is an effective treatment option for elderly patients with high-grade NHL and has comparable efficacy with other published regimens. The use of such low-dose doxorubicin-containing regimens in elderly patients with high-grade NHL requires further investigation.
Affiliation:
Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester, UK.
Citation:
A doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphoma. 2000, 12 (3):153-7 Clin Oncol
Journal:
Clinical Oncology
Issue Date:
2000
URI:
http://hdl.handle.net/10541/85440
DOI:
10.1053/clon.2000.9142
PubMed ID:
10942331
Type:
Article
Language:
en
ISSN:
0936-6555
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorWylie, James Pen
dc.contributor.authorCowan, Richard Aen
dc.contributor.authorRadford, John Aen
dc.contributor.authorDeakin, David Pen
dc.contributor.authorHarris, Maggie Aen
dc.contributor.authorWilkinson, Peter Men
dc.date.accessioned2009-11-05T16:00:46Z-
dc.date.available2009-11-05T16:00:46Z-
dc.date.issued2000-
dc.identifier.citationA doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphoma. 2000, 12 (3):153-7 Clin Oncolen
dc.identifier.issn0936-6555-
dc.identifier.pmid10942331-
dc.identifier.doi10.1053/clon.2000.9142-
dc.identifier.urihttp://hdl.handle.net/10541/85440-
dc.description.abstractA retrospective analysis was performed on 66 patients, aged 70 years or older, who received treatment with a weekly doxorubicin-containing regimen (VAPEC-B) for high grade non-Hodgkin's lymphoma (NHL). Two dosing schedules were employed. The choice of regimen was at the discretion of the treating clinician and reflected the performance status of the patient and the predicted tolerance to chemotherapy. Forty-nine patients received a half-dose schedule and 17 the full-dose schedule. Those receiving the half-dose regimen had a lower median performance status and received a lower dose intensity of chemotherapy (45% versus 83%). However, the outcomes of the two groups were similar: complete remission rate 41% versus 47%, and 5-year overall survival 36% versus 23%, for the half- and full-dose groups, respectively. A similar proportion of patients (51% versus 59%) completed each regimen, although there were more delays in treatment delivery experienced in those receiving the full dose. Half-dose VAPEC-B is an effective treatment option for elderly patients with high-grade NHL and has comparable efficacy with other published regimens. The use of such low-dose doxorubicin-containing regimens in elderly patients with high-grade NHL requires further investigation.en
dc.language.isoenen
dc.subject.meshAged-
dc.subject.meshAntibiotics, Antineoplastic-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBleomycin-
dc.subject.meshCyclophosphamide-
dc.subject.meshDoxorubicin-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshEtoposide-
dc.subject.meshHumans-
dc.subject.meshLymphoma, Non-Hodgkin-
dc.subject.meshRetrospective Studies-
dc.subject.meshSurvival Rate-
dc.subject.meshVincristine-
dc.titleA doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalClinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.